score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat57		
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		MEL-IPI_Pat57	MEL-IPI_Pat57-Tumor-SM-4DK2I	
Biologically Relevant				Copy Number	MTOR	Amplification				0.0	0.0																					0				MTOR Amplification		MEL-IPI_Pat57	MEL-IPI_Pat57-Tumor-SM-4DK2I	
Biologically Relevant				Copy Number	GATA3	Amplification				0.0	0.0																					0				GATA3 Amplification		MEL-IPI_Pat57	MEL-IPI_Pat57-Tumor-SM-4DK2I	
Biologically Relevant				Copy Number	SLC45A3	Deletion				0.0	0.0																					0				SLC45A3 Deletion		MEL-IPI_Pat57	MEL-IPI_Pat57-Tumor-SM-4DK2I	
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.411																									0				COSMIC Signature (version 2) 1 (41%)		MEL-IPI_Pat57		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.52																									0				COSMIC Signature (version 2) 7 (52%)		MEL-IPI_Pat57		
